此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

APHP Plateform of Normothermic Perfusion for Rehabilitation of Hepatic Grafts (PENOFOR)

2019年11月4日 更新者:Assistance Publique - Hôpitaux de Paris

APHP Plateform for Assessement of Hepatic Grafts Initialy Discarded by Normothermic Perfusion

This study aimed to evaluate fatty liver grafts, considered as unsuitable for upfront liver transplantation, by using normothermic perfusion. Grafts have to be allocated to one of 3 liver transplantation centres of Paris. After evidence of viability while on perfusion, these grafts will be transplanted to recipients with an estimated waiting time > 6 months.

研究概览

详细说明

In this study, the coordinator investigator proposes to build a platform for perfusing in normothermic conditions all grafts with histologically proven macrosteatosis ≥ 30% that will be considered as unsuitable for upfront LT. These grafts have to be alloacted to one of the 3 liver transplantation centers of Assistance Publique des Hôpitaux de Paris. Eligible grafts (macrosteatosis ≥ 30%, no severe fibrosis or cirrhosis) will be shipped to the platform for normothermic perfusion. Perfusion will be started provided that cold ischemia time do not exceed 8 hours. Parameters of grafts viability (lactates, bile production, flow) will be monitored. After a minimum of 4 hours of normothermic perfusion (not exceeding 16 hours), grafts fulfilling strict criteria (homogeneous aspect of the liver without any necrotic regions, lactates < 2.5 mmol/l and continuous production of bile with at least one of the following criteria: pH of perfusate > 7.3, arterial flow > 150 ml/min and portal flow > 500 ml/min, homogeneous perfusion of the graft) will be considered suitable for transplantation. Recipient will be transferred to the operating room, and first phase of LT (i.e, laparotomy and total hepatectomy) will be started. Simultaneously, grafts will be shipped to the center of initial allocation. Perfusion will be pursued during the transport from the platform to the recipient. Recipients (≥18 years and ≤ 70 years) have to be enlisted for LT with an estimated waiting time > 6 months (i.e., MELD score < 25) and who signed an informed consent.

研究类型

介入性

注册 (预期的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Villejuif、法国、94800
        • AP-HP, Paul Brousse Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • patients enlisted for liver transplantation for liver disease or HCC (AFP score≤ 2);
  • Ongoing cotraception in women of reproductive age ;
  • Patient with social security ;
  • informed signed consent

Exclusion criteria:

  • Extra-hepatic tumor disease;
  • Re-transplantation ;
  • Pregnancy or brest-feeding;
  • Patients participting in another study;
  • Patients under psychiatric treatment;
  • Patients under tutorship or curatorship

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Normothermic perfusion of a graft
Liver transplantation of a graft after assessment by normothermic perfusion

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To determine the proportion of grafts that can be transplanted after evaluation by normothermic perfusion (Hypothesis 50%) with a 3-year graft survival ≥ 90%
大体时间:3 months
Graft survival
3 months

次要结果测量

结果测量
措施说明
大体时间
Proportion of hepatic grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period
大体时间:36 months
Proportion of hepatic grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period
36 months
Proportion of fatty grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period eligible for normothermic perfusion
大体时间:36 months
Proportion of fatty grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period eligible for normothermic perfusion
36 months
Proportion of grafts perfused
大体时间:36 months
Proportion of grafts perfused
36 months
Proportion of grafts that were transplanted after perfusion
大体时间:36 months
Proportion of grafts that were transplanted after perfusion
36 months
Time interval until liver function recovery while on normothermic perfusion (according to viability criteria defined above)
大体时间:15 hours
Time interval until liver function recovery while on normothermic perfusion (according to viability criteria defined above)
15 hours
Proportions of grafts transplanted after normotheric perfusion wthout early allograft dysfunction (according to Olthoff definition)
大体时间:one month
Proportions of grafts transplanted after normotheric perfusion wthout early allograft dysfunction (according to Olthoff definition)
one month
Time interval until liver function recovery after transplantation
大体时间:one day
Time interval until liver function recovery after transplantation
one day
One-month overall survival (without retransplantation or graft dysfunction)
大体时间:one month
One-month overall survival (without retransplantation or graft dysfunction)
one month
One -year graft survival
大体时间:one year
One -year graft survival
one year
Comparison of 3-months graft survival with a control group of graft considered as initially transplantable
大体时间:3 months
Comparison of 3-months graft survival with a control group of graft considered as initially transplantable
3 months
Waiting time between the two groups
大体时间:36 months
36 months
Incidence of biliary stenosis (anastomotic or non anastomotic) defined by cholangio MRI at one year
大体时间:12 months
Incidence of biliary stenosis (anastomotic or non anastomotic) defined by cholangio MRI at one year
12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2019年10月28日

初级完成 (预期的)

2021年7月1日

研究完成 (预期的)

2022年4月1日

研究注册日期

首次提交

2019年8月21日

首先提交符合 QC 标准的

2019年11月4日

首次发布 (实际的)

2019年11月6日

研究记录更新

最后更新发布 (实际的)

2019年11月6日

上次提交的符合 QC 标准的更新

2019年11月4日

最后验证

2019年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • P170605J

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅